Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

2025-522888-15-00 Protocol 20250114 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 27 May 2026 · Status Authorised, recruiting · 5 EU/EEA countries · 17 sites · Protocol 20250114

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 160
Countries 5
Sites 17

Small Cell Lung Cancer

Key facts

Sponsor
Amgen Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 May 2026 → ongoing
Decision date (initial)
2026-05-11
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2025-522888-15-00
WHO UTN
U1111-1330-7464

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Small Cell Lung Cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10041068 Small cell lung cancer extensive stage 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Amgen Inc.

Sponsor organisation
Amgen Inc.
Address
1 Amgen Center Drive
City
Thousand Oaks
Postcode
91320-1730
Country
United States

Scientific contact point

Organisation
Amgen Inc.
Contact name
Medical Information

Public contact point

Organisation
Amgen Inc.
Contact name
Medical Information

Locations

5 EU/EEA countries · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Authorised, recruitment pending 9 3
France Authorised, recruitment pending 11 3
Germany Authorised, recruiting 11 3
Poland Authorised, recruitment pending 10 3
Spain Authorised, recruitment pending 12 5
Rest of world
Turkey, Australia, Korea, Republic of, United States, Switzerland
107

Investigational sites

Belgium

3 sites · Authorised, recruitment pending
Institut Jules Bordet
Medical Oncology, Mijlenmeersstraat 90, 1070, Anderlecht
Ziekenhuis Aan De Stroom
Medical Oncology, Oosterveldlaan 24, 2610, Antwerp
Universitair Ziekenhuis Gent
Medical Oncology, Corneel Heymanslaan 10, 9000, Gent

France

3 sites · Authorised, recruitment pending
Hospices Civils De Lyon
Pulmonology Department, 59 Boulevard Pinel, 69500, Bron
Institut Gustave Roussy
Early Drug Development Department (DITEP), 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Hospitalier Regional De Marseille
Marseille Early Phase Oncology Clinical Trials Unit, 264 Rue Saint Pierre, 13005, Marseille

Germany

3 sites · Authorised, recruiting
Charite Universitaetsmedizin Berlin KöR
Hematology, oncology and tumor immunology, Hindenburgdamm 30, Lichterfelde, Berlin
Universitaetsklinikum Wuerzburg AöR
Comprehensive Cancer Center Mainfranken, Straubmuehlweg 2a, Grombuehl, Wuerzburg
Technische Universitaet Dresden
NCT Early Clinical Trial Unit, Fetscherstrasse 74, Johannstadt-Nord, Dresden

Poland

3 sites · Authorised, recruitment pending
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Oncology, Ul. Wybrzeze Armii Krajowej 15, 44-102, Gliwice
Uniwersyteckie Centrum Kliniczne
Oncology, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Oncology, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw

Spain

5 sites · Authorised, recruitment pending
Hospital Universitari Vall D Hebron
Servicio de Oncologia, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Virgen De La Victoria
Servicio de Oncologia, Campus De Teatinos Sn, Puerto De La Torre, Malaga
Hospital Universitario 12 De Octubre
Servicio de Oncologia, Avenida De Cordoba Sn, 28041, Madrid
Hospital Clinico Universitario De Valencia
Servicio de Hematologia y Oncologia, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Ramon Y Cajal
Servicio de Oncologia, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-05-27

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-28 Belgium Acceptable
2026-05-04
2026-05-05